Legal 500
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • News & Developments
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • News & Developments
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Data Protection policies
  • Cookies Policy
  • Supplier Code of Conduct
  • Modern Slavery and Human Trafficking Statement
  • Contact Us
  • home
  • Intelligence
  • Search

550 results found

Use advanced search filters to refine your search

1 filter applied

Advanced search filters

Topics
Countries
Contributor
Content type
Show options
  • Article

    Patent Box - Patent Strategy Considerations

    The Patent Box makes the existence of a patent more attractive, whatever the breadth of the patent's claim, so long as it covers the product (or process or service).
    United KingdomIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Marking Products As Patented In The UK

    In the UK, marking patented products as patented is not compulsory. However, there are several benefits to marking products as patented and both guidance from the UK Intellectual Property Office, and UK law...
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
Article

Sanofi & Regeneron v Amgen: The UPC Weighs In On Infringement Of Second Medical Use Claims

Patent protection for the use of a known drug in a new method of medical treatment can be achieved at the European Patent Office via a second medical use claim in the format [known drug] for use...
United StatesIntellectual Property
J A Kemp
J A Kemp
  • Article

    UPC COA Establishes Key Principles For Inventive Step And Medical Use Inventions

    In a significant decision issued 25 November 2025, the UPC COA has held Amgen's anti-PCSK9 antibody medical use patent to be inventive...
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Alphafold – A Game Changer In Machine Learning Research

    Proteins are a class of macromolecules which carry out a wide range of functions. For example, proteins are essential for photosynthesis, producing energy from food, contracting muscle fibres and DNA replication,...
    United KingdomFood, Drugs, Healthcare, Life Sciences
    J A Kemp
    J A Kemp
  • Article

    COP28 Series: Genetic Technologies

    Food systems are responsible for a third of anthropogenic greenhouse gas emissions, and already half of the world's habitable land is devoted to agriculture.
    United StatesEnvironment
    J A Kemp
    J A Kemp
  • Article

    UPC vs EPO: Key Procedural Differences In Challenges To Patent Validity

    A notorious aspect of proceedings at the UPC is their frontloaded nature, according to which parties are required to set out their full case as early as possible.
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Disclaimer Practice At The EPO

    The European Patent Office (EPO) uses the term "disclaimer" to refer to a negative feature in a claim of a patent application. Negative features are those which exclude certain subject-matter from the scope of protection.
    European UnionLitigation, Mediation & Arbitration
    J A Kemp
    J A Kemp
  • Article

    Data Exclusivity And Market Protection In The EU / EEA And UK

    In order to place a new medicinal product on the market in Europe, it is necessary first to obtain a marketing authorisation.
    GlobalMedia, Telecoms, IT, Entertainment
    J A Kemp
    J A Kemp
  • Article

    AG's Opinion In Royalty Pharma C-650/17 And Sandoz C-114/18 Signals A Tougher Approach To Article 3(a) Of The SPC Regulation

    It was developed after the filing date of the basic patent by a licensee which obtained a patent for it, on the basis of which it was granted its own SPC.
    United KingdomIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Patent Box – Patent Strategy Considerations

    The Patent Box makes the existence of a patent more attractive, whatever the breadth of the patent's claim, so long as it covers the product (or process or service).
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Referral G1/26: Claim Interpretation And Added Subject Matter After G1/24

    The European Patent Office's Board of Appeal has referred critical questions to the Enlarged Board of Appeal concerning how patent claims should be interpreted when assessing added subject matter. The referral, pending as G1/26, seeks to clarify whether features from descriptions and drawings can be imported into claim interpretation, and which claim interpretations must be disclosed in the original application to avoid added matter objections.
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    UK High Court Upholds Novartis’s Sacubitril Valsartan SPC: What Is The Relevant “product”?

    The UK High Court has rejected a challenge to Novartis's supplementary protection certificate for sacubitril and valsartan, addressing a fundamental question about how the "product" protected by an SPC should be defined. The decision clarifies whether a specific co-crystal formulation or the broader combination of active ingredients constitutes the relevant product under the SPC Regulation.
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    UK Registered Design Infringement: The Battle Against Look-a-Likes

    British retailer Marks and Spencer (M&S) recently succeeded in proceedings brought against budget supermarket chain, Aldi, for infringement of its UK registered design rights.
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Antibodies In The European Patent Office - Basic Principles

    Over recent years, antibodies have become increasingly important as therapeutic drugs and large numbers of patent applications are filed in this area (>1000 granted by the European Patent Office (EPO) in 2019).
    European UnionIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    The UPC's Evolving Approach To Inventive Step

    It has now been over two years since launch of the UPC. A key question for users was what the court's approach to assessment of validity would be in practice. In this briefing, we review the approach the UPC has taken...
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    An Introduction To IP Considerations For Technology-Based Business Ventures

    Inventors are often unaware of the potential variety of IP rights they could obtain to protect their technology, particularly design rights and how they can complement patents.
    United KingdomIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Protecting Your IP When Crowdfunding

    Crowdfunding can be a great way of raising funds. However, if you fund your business in this way you need to consider carefully how to protect your valuable intellectual property (IP).
    United KingdomIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Dyson v Dreame: UPC Court Of Appeal Refers Long-arm Jurisdiction Questions To CJEU

    In UPC_CoA_789/2025 and UPC_CoA_813/2025, 6 March 2026, Dyson v Dreame, the Court of Appeal has partially stayed proceedings and referred four questions to the CJEU.
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Article

    Patents And University Spin-outs: Protecting Academic Innovation

    Universities drive innovation across medicine, AI, materials, and clean tech, but academic researchers face a critical challenge: the need to publish conflicts with patent protection requirements for confidentiality. Understanding how to navigate publication deadlines, filing strategies, and IP development can determine whether groundbreaking research becomes a valuable commercial asset or loses protection entirely.
    United StatesIntellectual Property
    J A Kemp
    J A Kemp
  • Showing 441–460 of 550 results

    PreviousNext
    Legal Intelligence Newsletters